Verastem
Aug 11, 2020
FDA’s Ok to Roche’s Oral SMA Therapy; Roche’s Etrolizumab Mixed Results in Ulcerative Colitis; Secura receives rights to Copiktra from Verastem
Roche Set to Compete With Biogen and Novartis in the SMA Market With its First Oral Therapy The US FDA has recommended the use of Evrysdi (risdiplam), a candidate of Genentech, a Roche company, for spinal muscular atrophy (SMA), an inherited neuromuscular disease resulting in muscle atrophy, in adults and...
Read More...
Jan 13, 2020
Malignant pleural mesothelioma market: Elusive treatment approaches and Poor diagnosis
Malignant pleural mesothelioma (MPM) is a malignancy of pleural layers within the lung cavity and inner sides of the ribs. Year of research has revealed asbestos exposure as the primary cause of the malignancy. The longer the asbestos exposure, more is the risk of a person developing mesothelioma. It...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
